Table 1.
Study characteristics
| Author, study, year, references | Strata | n case/control | Country | Cancer | Funding | Rand | Status | Timeline |
|---|---|---|---|---|---|---|---|---|
| Augustin (2005) | 1 | 329/357 | DE, CH | Skin | Foundational | No | Observational | Retrolective |
| Dold (1991) | 1 | 114/113 | DE | Lung | Public/Institutional | Yes | Interventional | Prospective |
| Fellmer (1966) | 2 | 81/800 | DE | Gynecological | Foundational | No | Interventional | Prospective |
| Fritz (2018) | 2 | 164/18364 | DE | Breast | Foundational | No | Observational | Retrospective |
| Grossarth-Maticek CORPUS (2008) | 3 | 198/198 | DE | Gynecological | Foundational and public | No | * | Prospective |
| Grossarth-Maticek CORPUSRAND (2008) | 3 | 56/56 | DE | Gynecological | Foundational and public | Yes | * | Prospective |
| Grossarth-Maticek OVAR (2007a) | 3 | 137/137 | DE | Gynecological | Foundational and public | No | * | Prospective |
| Grossarth-Maticek OVARRAND (2007a) | 3 | 41/41 | DE | Gynecological | Foundational and public | Yes | * | Prospective |
| Grossarth-Maticek CervixMetRand (2007b) | 1 | 19/19 | DE | Gynecological | Foundational and public | Yes | * | Prospective |
| Grossarth-Maticek CERVIX (2007b) | 3 | 168/168 | DE | Gynecological | Foundational and public | No | * | Prospective |
| Grossarth-Maticek Melanoma (2007c) | 1 | 32/32 | DE | Skin | Not reported | No | * | Prospective |
| Grossarth-Maticek MelanomaRand (2007c) | 1 | 22/22 | DE | Skin | Not reported | Yes | * | Prospective |
| Grossarth-Maticek Mamma (2006a) | 1 | 84/84 | DE | Breast | Foundational and public | No | * | Prospective |
| Grossarth-Maticek MammaRand (2006a) | 1 | 38/38 | DE | Breast | Foundational and public | Yes | * | Prospective |
| Grossarth-Maticek MammaRec (2006b) | 1 | 42/42 | DE | Breast | Foundational and public | No | * | Prospective |
| Grossarth-Maticek MammaLym (2006b) | 1 | 55/55 | DE | Breast | Foundational and public | No | * | Prospective |
| Grossarth-Maticek MammaMet (2006b) | 1 | 83/83 | DE | Breast | Foundational and public | No | * | Prospective |
| Grossarth-Maticek MammaLymRand (2006b) | 1 | 17/17 | DE | Breast | Foundational and public | Yes | * | Prospective |
| Grossarth-Maticek (2004) | 1 | 49/49 | DE | Multiple | Foundational and public | Yes | * | Prospective |
| Grossarth-Maticek Full population strict (2001) | 1 | 396/396 | DE | Multiple | Foundational and public | No | * | Prospective |
| Grossarth-Maticek Rand balanced (2001) | 1 | 49/49 | DE | Multiple | Foundational and public | Yes | * | Prospective |
| Grossarth-Maticek Subgroups cancer type (2001) | 5 | 276/276 | DE | Multiple | Foundational and public | No | * | Prospective |
| Günczler Mamma (1969) | 2 | 257/153 | AT | Breast | Not reported | No | Interventional | Retrospect. control group |
| Günczler Colon (1969) | 1 | 47/91 | AT | Gastrointestinal | Not reported | No | Interventional | Prospective |
| Günczler (1968) | 4 | 67/101 | AT | Gastrointestinal | Not reported | No | Interventional | Prospective |
| Hassauer (1979) | 4 | 25/22 | DE | Gynecological | Not reported | No | Interventional | Retrospect. control group |
| Hoffmann (1982) | 6 | 254/241 | DE, CH | Breast | Not reported | No | Interventional | Retrospect. control group |
| Hoffmann(1979) | 2 | 188/122 | DE, CH | Multiple | Not reported | No | Interventional | Retrospect. control group |
| Kleeberg (2004) | 3 | 102/102 | ** | Skin | Public and corporate | Yes | Interventional | Prospective |
| Leroi (1977) | 2 | 319/228 | CH | Breast | Not reported | No | Observational | Retrospective |
| Leroi (1975) | 1 | 81/30 | DE, CH | Breast | Not reported | No | Interventional | No Information |
| Longhi (2020a, b) | 1 | 9/10 | IT | Osteosarcoma | None | Yes | Interventional | Prospective |
| Matthes (2010) | 5 | 201/195 | DE, CH | Gastrointestinal | Foundational | No | Observational | Retrolective |
| Salzer (1991) | 4 | 86/97 | DE, AT | Lung | Not reported | Yes | Interventional | Prospective |
| Salzer (1985) | 6 | 37/40 | AT | Lung | Corporate | No | Observational | Retrospective |
| Salzer (1983) | 2 | 62/75 | AT | Gastrointestinal | Not reported | Yes | Interventional | Prospective |
| Schmidt (2007) | 1 | 710/732 | DE | Breast | Not reported | No | Observational | Retrolective |
| Schuppli (1990) | 1 | 84/114 | CH | Skin | Not reported | No | Interventional | Prospective |
| Tröger (2013) | 5 | 110/110 | RS | Gastrointestinal | Foundational | Yes | Interventional | Prospective |
Strata data strands identified within publications with individual patient and survival data, Gynecological Cancer Other than Breast Cancer, Rand randomization
*Intervention consisted of suggesting that the patient discuss mistletoe therapy with their doctor
**Countries in which the conduction of the study of Kleeberg (2004) took place: DE, FR, CH, AT, BE, UK, YU, IL, CZ, EE, GR, SP, and PL